Page last updated: 2024-09-03

n,n-dimethylarginine and tolafentrine

n,n-dimethylarginine has been researched along with tolafentrine in 2 studies

Compound Research Comparison

Studies
(n,n-dimethylarginine)
Trials
(n,n-dimethylarginine)
Recent Studies (post-2010)
(n,n-dimethylarginine)
Studies
(tolafentrine)
Trials
(tolafentrine)
Recent Studies (post-2010) (tolafentrine)
2,2162281,2211012

Protein Interaction Comparison

ProteinTaxonomyn,n-dimethylarginine (IC50)tolafentrine (IC50)
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.03

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fleming, I; Ghofrani, HA; Grimminger, F; Leiper, J; Mayer, K; Pullamsetti, SS; Savai, R; Schaefer, MB; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N; Wilhelm, J1
Talukder, MA; Zweier, JL1

Other Studies

2 other study(ies) available for n,n-dimethylarginine and tolafentrine

ArticleYear
cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases.
    Circulation, 2011, Mar-22, Volume: 123, Issue:11

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amidohydrolases; Apoptosis; Arginine; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclic GMP; Cytokines; Endothelial Cells; Hemodynamics; Humans; Hypertension, Pulmonary; Naphthyridines; Nitric Oxide; Phosphodiesterase Inhibitors; Promoter Regions, Genetic; Pulmonary Gas Exchange

2011
Targeting dimethylarginine dimethylaminohydrolases in pulmonary arterial hypertension: a new approach to improve vascular dysfunction?
    Circulation, 2011, Mar-22, Volume: 123, Issue:11

    Topics: Amidohydrolases; Arginine; Humans; Hypertension, Pulmonary; Naphthyridines; Nitric Oxide; Nitric Oxide Synthase; Phosphodiesterase Inhibitors

2011